Genomic Test Predicts Which Prostate Cancer Patients Benefit From Abiraterone Therapy
The test can help identify which prostate cancer patients will benefit from adding the hormonal therapy abiraterone to their standard care.
Study findings show tissue-based molecular test scores correlate with distant metastasis and mortality risk, offering a tool to guide treatment intensification. Veracyte’s Decipher tissue-based molecular test can help identify which patients with hig... [3109 chars]
Read the full report on Clinical Lab Products
Story file
- Section
- Health
- Topics
- Health alerts
- First reported by
- Clinical Lab Products
- Published
- Friday, 23 October 2026, 8:42 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Clinical Lab Products with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
